Lam Jerika T, Xavioer Sharon
Department of Pharmacy Practice, Chapman University School of Pharmacy, 9401 Jeronimo Rd. Ste 207, Ste 296, Irvine, CA 92618, USA.
Pharmacy (Basel). 2024 Jul 24;12(4):115. doi: 10.3390/pharmacy12040115.
Pharmacists are key players who can help to eliminate the hepatitis C virus (HCV) epidemic in the United States. This pilot retrospective study evaluated the impact of a pharmacist-led HCV treatment program in a federally qualified health center (FQHC) primary care clinic setting. The primary outcome was to assess sustained virologic response (SVR) rates 12 weeks after patients were initiated and completed their oral direct acting antiviral (DAA) treatment regimens.
This pilot retrospective study included historical analyses of patients who received DAA treatment in the pharmacist-led HCV treatment program in a FQHC clinic between 1 January 2019 and 31 January 2021. SVR was the primary outcome measure for treatment response.
Sixty-seven patients with HCV mono- and HIV co-infection were referred, and 59 patients were initiated on DAA regimens after treatment. Fifty of those who were started on DAA regimens completed their treatment, and 38 achieved SVR (modified intention to treat [mITT] SVR rate of 76%).
Our study's findings demonstrated SVR rates that were comparable with other pharmacist-directed HCV treatment services in the United States despite the impact of the COVID-19 pandemic. Our study included a higher proportion of individuals with HCV/HIV co-infection and of Hispanic ethnicity.
药剂师是有助于在美国消除丙型肝炎病毒（HCV）流行的关键角色。这项试点回顾性研究评估了在联邦合格健康中心（FQHC）初级保健诊所环境中由药剂师主导的HCV治疗项目的影响。主要结局是评估患者开始并完成口服直接抗病毒药物（DAA）治疗方案12周后的持续病毒学应答（SVR）率。
这项试点回顾性研究包括对2019年1月1日至2021年1月31日期间在FQHC诊所的药剂师主导的HCV治疗项目中接受DAA治疗的患者的历史分析。SVR是治疗反应的主要结局指标。
67例HCV单感染和HIV合并感染患者被转诊，59例患者在治疗后开始使用DAA方案。在开始使用DAA方案的患者中，50例完成了治疗，38例实现了SVR（改良意向性治疗[mITT]SVR率为76%）。
我们研究的结果表明，尽管受到新冠疫情的影响，SVR率与美国其他由药剂师指导的HCV治疗服务相当。我们的研究纳入了更高比例的HCV/HIV合并感染个体和西班牙裔个体。
